Program
HRS-1301
A development code. Also written as “HRS-1301 Tablets” and “HRS-1301 Tablet”.
Its studies are mostly in Hyperlipidemias, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 51 open or running | phase 2since Nov 14, 2025 | Feb 27, 2025 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-1301
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2025First study: phase 1 study in HyperlipidemiasFirst studyNCT06857253 · 84 enrolled · China
- Jul 24, 2025Phase 1 study in HyperlipidemiasNCT07097831 · 16 enrolled · China
- Nov 14, 2025Phase 2 study in HyperlipidemiasNCT07229937 · 189 planned · China
- Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07322016 · 36 enrolled · China
- May 20, 2026Phase 1 study in HyperlipidemiasNCT07608705 · 16 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07608705Hyperlipidemias · China | 1 | Completed | Aug 24, 2026 | 16 |
| NCT07322016Hyperlipidemias · China | 1 | Completed | Aug 4, 2026 | 36 |
| NCT07229937Hyperlipidemias · China | 2 | Recruiting | Aug 2026 | 189 |
| NCT07097831Hyperlipidemias · China | 1 | Completed | Nov 7, 2025 | 16 |
| NCT06857253Hyperlipidemias · China | 1 | Completed | Aug 12, 2025 | 84 |
How it is read
Names in the registry
- “HRS-1301”, 5 entries
- “HRS-1301 Tablets”, 2 entries
- “HRS-1301 Tablet”, 1 entry
Codes read as this program: HRS1301.
Conditions, from the studies’ own filings
- Hyperlipidemias, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.